SABS vs. VSTM, CRIS, FBIO, BOLT, MTEM, AMGN, VRTX, REGN, GILD, and BIIB
Should you be buying SAB Biotherapeutics stock or one of its competitors? The main competitors of SAB Biotherapeutics include Verastem (VSTM), Curis (CRIS), Fortress Biotech (FBIO), Bolt Biotherapeutics (BOLT), Molecular Templates (MTEM), Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Gilead Sciences (GILD), and Biogen (BIIB). These companies are all part of the "biotechnology" industry.
Verastem (NASDAQ:VSTM) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, community ranking and risk.
Verastem has a net margin of 0.00% compared to Verastem's net margin of -1,531.26%. Verastem's return on equity of -109.90% beat SAB Biotherapeutics' return on equity.
Verastem has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500. Comparatively, SAB Biotherapeutics has a beta of 0.63, suggesting that its stock price is 37% less volatile than the S&P 500.
Verastem received 578 more outperform votes than SAB Biotherapeutics when rated by MarketBeat users. However, 76.92% of users gave SAB Biotherapeutics an outperform vote while only 65.28% of users gave Verastem an outperform vote.
SAB Biotherapeutics has lower revenue, but higher earnings than Verastem.
In the previous week, Verastem and Verastem both had 2 articles in the media. SAB Biotherapeutics' average media sentiment score of 0.00 equaled Verastem'saverage media sentiment score.
88.4% of Verastem shares are held by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are held by institutional investors. 2.2% of Verastem shares are held by insiders. Comparatively, 26.5% of SAB Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Verastem presently has a consensus price target of $25.69, suggesting a potential upside of 655.51%. SAB Biotherapeutics has a consensus price target of $13.00, suggesting a potential upside of 342.18%. Given SAB Biotherapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Verastem is more favorable than SAB Biotherapeutics.
Summary
Verastem beats SAB Biotherapeutics on 9 of the 14 factors compared between the two stocks.
Get SAB Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SABS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SABS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SAB Biotherapeutics Competitors List
Related Companies and Tools
